查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371891

到 2030 年的全球生技药品市场预测：按产品、类型、用途和地区进行的全球分析

Biologic Therapeutics Market Forecasts to 2030 - Global Analysis By Product (Gene Therapy, Cell Therapy, Vaccines, Antibody Therapeutics and Other Products), Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球生技药品市场规模为 4,575.6 亿美元，预计将以 11.3% 的年复合成长率成长，到 2030 年达到 9,680.8 亿美元。

专注于生物来源治疗药物的开发、生产和行销的製药工业部门被称为生技药品市场。这些复杂的化学物质是利用活生物体或活生物体的一部分製成的，例如蛋白质、抗体、核酸和细胞。又称生技药品或生物製药。

据世界卫生组织 (WHO) 称，疫苗是减轻全球疾病负担最有力、最具成本效益的方法之一，预计每年可挽救 200-300 万人的生命。

与老龄化相关的慢性病的增加和生技药品管道的扩大

癌症、自体免疫疾病和代谢性疾病等慢性疾病的增加增加了对有效替代疗法的需求。生技药品提供量身定制的、标靶治疗，可以解决许多疾病的根本原因，从而推动市场扩张。此外，生技药品开发还获得了製药和生物技术行业的大量资金。重组蛋白、细胞和基因疗法以及单株抗体等生技药品的发展正在重振市场并刺激创新。

开发、生产、製造和供应链管理成本高且极为复杂。

开发和製造生技药品需要复杂的程序和大量的成本，包括研发、临床试验和製造设施。这些高成本可能会限制生技药品的可得性和可负担性，特别是在资源有限的医疗保健系统中。然而，由于其复杂性，生技药品需要专门的生产设施和程序。确保一致的品质、可扩展性和维持强大的供应链可能很困难，并且会影响生技药品治疗的可及性和可负担性。

生物技术和基因工程的进步以及有利的法规条件

生物技术、基因工程和重组 DNA 技术的进步正在增加创造创新生物疗法的潜力。这些技术的发展使得能够生产更复杂、更有特异性的生物药品，扩大了可用治疗方法的数量。此外，欧洲药品管理局（EMA）和美国食品药物管理局（FDA）等法规机构也为生技药品的核准制定了精确的规则并​​加快了核准程序。这些管理体制为生技药品的开发、评估和行销提供了有利的环境。

高水准的法规以及对免疫抗原性和安全性的担忧

儘管有有利的法律规范，但生技药品的核准过程复杂且要求严格。公司必须进行广泛的临床前和临床试验来证明安全性、有效性和品质，这需要很长时间并花费大量资金。然而，可能会诱导患者对生物治疗的免疫反应，引发对其安全性和免疫抗原性的担忧。这些免疫反应会不同程度地影响治疗的有效性和安全性。有效监测和管理此类问题对于有效使用生物治疗至关重要。

COVID-19 的影响

COVID-19 的爆发使得高效的疫苗生产和分发变得至关重要。因此，利用 mRNA 和病毒载体疫苗等生物平台进行的疫苗研发显着增加。 COVID-19疫苗的有效研发和应用凸显了生物治疗的前景，并强调了生物技术领域在感染疾病控制中的重要性。

血液製品领域预计在预测期内规模最大

预测期内，血液製品领域占据最大份额。血液衍生产品，包括免疫球蛋白、凝血因子和血浆衍生蛋白，用于治疗各种血液疾病和免疫力缺乏，也被认为是生物疗法的一部分。这些物品的使用对于治疗许多血液疾病、免疫力缺乏和其他疾病至关重要。

预计细胞治疗领域在预测期内将经历最高的年复合成长率。

据估计，细胞治疗领域在预测期内将出现良好的成长。活细胞用于细胞疗法来治疗和治癒疾病。细胞疗法是一个快速发展的领域，旨在替换、修復和修復受损或患病的细胞和组织。此外，细胞疗法在许多治疗领域显示出潜力，包括肿瘤学、心血管疾病、神经退化性疾病疾病和自体免疫疾病。

比最大的地区

由于生物治疗行业经历了重大发展和创新，并正在成为一个充满活力和快速变化的中心，预计亚太地区将在预测期内占据最大份额。该地区与许多拥有自己的医疗保健系统的国家相连，使其成为一个复杂但有吸引力的市场。此外，癌症、糖尿病和自体免疫疾病等慢性疾病的流行增加了对生物治疗的需求。

复合年复合成长率最高的地区

据估计，亚太地区的年复合成长率最高。不断增长的中等收入人口和不断上涨的医疗保健费用正在扩大生物疗法的可用性。再加上政府鼓励医疗基础建设的政策，进一步推动了市场的成长。此外，亚太地区的研发活动蓬勃发展，国内外製药公司大力投资生技药品的开发。蓬勃发展的生物技术生态系统吸引人才并促进创新。该地区各国政府也正在努力简化核准程序，让生物製药公司更容易进入市场。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究来源
    • 主要研究来源
    • 二次研究来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球生技药品市场：依产品

  • 基因治疗
  • 细胞疗法
  • 疫苗
  • 抗体药物
  • 其他产品

第6章全球生技药品市场：依类型

  • 过敏原萃取物
  • 血液製品
  • 人体细胞和组织
  • 蛋白质
  • 异种移植产品
  • 其他类型

第7章全球生技药品市场：依用途

  • 自体免疫疾病
  • 感染疾病
  • 癌症
  • 其他用途

第8章全球生技药品市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Baxter International Inc
  • Biocon Ltd.
  • Celltrion Healthcare Co. Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc
  • Novartis AG
  • Pfizer Inc
  • Precision Biologics Inc
  • Samsung Electronics Co. Ltd
Product Code: SMRC23948

According to Stratistics MRC, the Global Biologic Therapeutics Market is accounted for $457.56 billion in 2023 and is expected to reach $968.08 billion by 2030 growing at a CAGR of 11.3% during the forecast period. The pharmaceutical industry sector that concentrates on the development, production, and marketing of therapeutic medicines generated from biological sources is referred to as the biologic therapeutics market. These complex chemicals are created using living organisms or their parts, such as proteins, antibodies, nucleic acids, or cells. They are also referred to as biologics or biological pharmaceuticals.

According to World Health Organization, vaccines are one of the most powerful and cost-effective ways to reduce the global burden of disease and are estimated to save 2-3 million lives every year.

Market Dynamics:

Driver:

Increasing prevalence of age-related and chronic diseases and expanding pipeline of biologics

The need for efficient treatment alternatives is being driven by the increased prevalence of chronic diseases like cancer, autoimmune conditions, and metabolic diseases. Biologic medicines provide customized, targeted treatments that can address the underlying causes of many disorders, spurring market expansion. Additionally, the development of biologic medicines has received significant funding from the pharmaceutical and biotechnology industries. Biologic medication development, including recombinant proteins, cell and gene therapies, and monoclonal antibodies, is boosting the market and spurring innovation.

Restraint:

High costs of development and production, manufacturing and supply chain management are quite complex

Complex procedures and high expenditures, such as those associated with research and development, clinical trials, and manufacturing facilities, are involved in the creation and production of biologic therapies. Particularly in healthcare systems with limited resources, these high costs may restrict the availability and affordability of biologic medications. However, due to their complicated nature, biologic pharmaceuticals need specialized production facilities and procedures. It can be difficult to ensure consistent quality, scaleability, and maintain a strong supply chain, which may have an impact on the accessibility and affordability of biologic treatments.

Opportunity:

Biotechnology and genetic engineering advancements and favorable regulatory landscape

The potential for creating innovative biological therapies has increased as a result of ongoing developments in biotechnology, genetic engineering, and recombinant DNA technology. These technological developments make it possible to produce biological medications that are more sophisticated and specifically targeted, expanding the number of available treatments. Additionally, regulatory organizations have established precise rules and accelerated paths for the approval of biologic therapies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). These regulatory regimes offer a favorable environment for the creation, assessment, and marketing of biologic medicines.

Threat:

High standards of regulation and concerns about immunogenicity and safety

Despite the existence of favorable regulatory frameworks, the complex and stringent approval procedures for biologic therapies. Extensive preclinical and clinical trials that must be conducted by companies to prove safety, efficacy, and quality can take a long time and cost a lot of funds. However, patients' immune responses to biological therapies may be induced, raising concerns regarding their safety and immunogenicity. The effectiveness and safety of the treatment may be impacted by these immunological reactions, which can range in severity. For biological treatments to be used effectively, it is crucial to provide effective monitoring and management of these problems.

COVID-19 Impact:

The COVID-19 epidemic made the creation and distribution of efficient vaccinations essential. As a result, vaccine research and development significantly increased, utilizing biological platforms like mRNA and viral vector-based vaccines. The effective creation and application of COVID-19 vaccines highlighted the promise of biological treatments and emphasized the significance of the biotechnology sector in combating infectious diseases.

The blood products segment is expected to be the largest during the forecast period

Blood products segment commanded the largest share over the forecast period. Blood-derived products, including immunoglobulins, clotting factors, and plasma-derived proteins, which are used to treat a variety of blood illnesses and immunological deficiencies, are also considered to be part of biologic therapies. The use of these items is essential in the management of a number of blood diseases, immunological deficiencies, and other ailments.

The cell therapy segment is expected to have the highest CAGR during the forecast period

Cell therapy segment is estimated to witness lucrative growth over the projection period. Living cells are used in cell therapy to treat or cure diseases. It is a fast-developing area that seeks to replace, restore, or fix damaged or sick cells or tissues. Additionally, cell therapy has demonstrated potential in a number of therapeutic fields, including oncology, cardiovascular illness, neurodegenerative disorders, and autoimmune diseases.

Region with largest share:

Asia Pacific is expected to hold largest share over the forecast period as the biological therapies industry experiences substantial development and innovation, the Asia-Pacific region is emerging as a vibrant and quickly changing hub. This region is connected to numerous nations with distinctive healthcare systems, making it a complex yet attractive market. Additionally, the region's growing need for biological treatments is being driven by the prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders.

Region with highest CAGR:

Asia Pacific is estimated to hold highest CAGR. The availability of biological therapies has expanded as a result of an expanding middle-class population and rising healthcare costs. This has further propelled the market's growth, along with government policies to encourage the construction of healthcare infrastructure. Additionally, the Asia-Pacific region is experiencing a boom in research and development activity, with both domestic and foreign pharmaceutical firms making significant investments in the development of biologic drugs. A thriving biotechnology ecosystem has resulted in an outcome that draws in talent and encourages innovation. Governments in the area are also making efforts to simplify approval procedures, improving the simplicity of market access for biopharmaceutical firms.

Key players in the market:

Some of the key players in Biologic Therapeutics Market include: AbbVie Inc, Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc, Biocon Ltd., Celltrion Healthcare Co. Ltd., GlaxoSmithKline Plc, Merck and Co. Inc, Novartis AG, Pfizer Inc , Precision Biologics Inc and Samsung Electronics Co. Ltd.

Key Developments:

In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announceD the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal

Products Covered:

  • Gene Therapy
  • Cell Therapy
  • Vaccines
  • Antibody Therapeutics
  • Other Products

Types Covered:

  • Allergenic Extracts
  • Blood Products
  • Human Cells and Tissues
  • Protein
  • Xenotransplantation Products
  • Other Types

Applications Covered:

  • Autoimmune Diseases
  • Infectious Diseases
  • Cancer
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologic Therapeutics Market, By Product

  • 5.1 Introduction
  • 5.2 Gene Therapy
  • 5.3 Cell Therapy
  • 5.4 Vaccines
  • 5.5 Antibody Therapeutics
  • 5.6 Other Products

6 Global Biologic Therapeutics Market, By Type

  • 6.1 Introduction
  • 6.2 Allergenic Extracts
  • 6.3 Blood Products
  • 6.4 Human Cells and Tissues
  • 6.5 Protein
  • 6.6 Xenotransplantation Products
  • 6.7 Other Types

7 Global Biologic Therapeutics Market, By Application

  • 7.1 Introduction
  • 7.2 Autoimmune Diseases
  • 7.3 Infectious Diseases
  • 7.4 Cancer
  • 7.5 Other Applications

8 Global Biologic Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AbbVie Inc
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca Plc
  • 10.4 Aurobindo Pharma Ltd.
  • 10.5 Baxter International Inc
  • 10.6 Biocon Ltd.
  • 10.7 Celltrion Healthcare Co. Ltd.
  • 10.8 GlaxoSmithKline Plc
  • 10.9 Merck and Co. Inc
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc
  • 10.12 Precision Biologics Inc
  • 10.13 Samsung Electronics Co. Ltd

List of Tables

  • Table 1 Global Biologic Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 4 Global Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 5 Global Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 6 Global Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 7 Global Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 10 Global Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 11 Global Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 12 Global Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 13 Global Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 14 Global Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 15 Global Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 17 Global Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 19 Global Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 20 North America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 23 North America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 24 North America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 25 North America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 26 North America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 27 North America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 28 North America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 29 North America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 30 North America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 31 North America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 32 North America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 33 North America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 North America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 North America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 36 North America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 37 North America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 38 North America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 39 Europe Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 42 Europe Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 43 Europe Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 44 Europe Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 45 Europe Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 46 Europe Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 48 Europe Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 49 Europe Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 50 Europe Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 51 Europe Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 52 Europe Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 53 Europe Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 54 Europe Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 55 Europe Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 56 Europe Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 57 Europe Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 58 Asia Pacific Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 61 Asia Pacific Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 62 Asia Pacific Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 63 Asia Pacific Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 64 Asia Pacific Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 65 Asia Pacific Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 67 Asia Pacific Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 68 Asia Pacific Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 69 Asia Pacific Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 70 Asia Pacific Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 72 Asia Pacific Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 73 Asia Pacific Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 74 Asia Pacific Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 75 Asia Pacific Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 76 Asia Pacific Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 77 South America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 80 South America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 81 South America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 82 South America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 83 South America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 84 South America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 85 South America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 86 South America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 87 South America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 88 South America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 89 South America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 90 South America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 91 South America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 92 South America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 93 South America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 94 South America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 95 South America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 96 Middle East & Africa Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 99 Middle East & Africa Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 100 Middle East & Africa Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 101 Middle East & Africa Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 102 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 103 Middle East & Africa Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 104 Middle East & Africa Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 105 Middle East & Africa Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 106 Middle East & Africa Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 107 Middle East & Africa Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 108 Middle East & Africa Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 109 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 110 Middle East & Africa Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 111 Middle East & Africa Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 112 Middle East & Africa Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 113 Middle East & Africa Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 114 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)